<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142760">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01690884</url>
  </required_header>
  <id_info>
    <org_study_id>120477</org_study_id>
    <nct_id>NCT01690884</nct_id>
  </id_info>
  <brief_title>Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake</brief_title>
  <official_title>Ticagrelor and Adenosine Uptake. Phase II Study Comparing the Effects of Ticagrelor vs Dipyridamole on Adenosine Uptake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are trying to determine if a single dose of Ticagrelor will increase
      delivery of intraarterially-infused adenosine into the forearm interstitium, consistent with
      adenosine reuptake blockade.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will compare adenosine interstitial levels using a parallel design study
      with three groups of subjects.  Forearm interstitial adenosine levels will be measured at
      baseline and after intrabrachial infusion of adenosine at two doses. Subjects will then
      randomly receive Ticagrelor 180 mg, Dipyridamole 200 mg, or placebo.  Two hours later the
      investigators will repeat the dialysate collections at baseline and after adenosine
      infusions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)</study_design>
  <primary_outcome>
    <measure>Interstitial levels of adenosine</measure>
    <time_frame>After each dose of intrabrachial adenosine</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>To determine if there is an increase in adenosine interstitial levels in the forearm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dipyridamole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To determine if there is an increase in adenosine interstitial levels in the forearm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine if there is an increase in adenosine interstitial levels in the forearm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine</intervention_name>
    <description>Adenosine will be infused into the brachial artery at 0.125 mg/min for 15 minutes and then at 0.5 mg/min for an additional 15 minutes,</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Dipyridamole</arm_group_label>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Adenocard</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects will be healthy volunteers, without significant pulmonary, cardiovascular
             gastrointestinal, hematological or renal diseases

          2. Not taking any regular medications

          3. Able to provide signed consent prior to study participation.

        Exclusion Criteria:

          1. History of asthma

          2. Pregnancy

          3. Exposure to an investigational drug in the last 2 months.

          4. Known hypersensitivity to study medications
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Italo Biaggioni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Italo Biaggioni, MD</last_name>
    <phone>(615)936-3420</phone>
    <email>adc.research@vanderbilt.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Autonomic Dysfunction Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Italo Biaggioni, M.D.</last_name>
      <phone>615-343-8010</phone>
      <email>adc.research@vanderbilt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alfredo Gamboa, M.D.</last_name>
      <phone>(615)-343-3649</phone>
      <email>adc.research@vanderbilt.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Italo Biaggioni, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfredo Gamboa, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyndya Shibao, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andre Diedrich, M.D., Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Satish Raj, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Okamoto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rocio A Figueroa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 12, 2014</lastchanged_date>
  <firstreceived_date>August 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Italo Biaggioni</investigator_full_name>
    <investigator_title>Professor of Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <keyword>Adenosine</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Microdialysis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenosine</mesh_term>
    <mesh_term>Dipyridamole</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
